| Today's Top Story |  |  | | - Report: Drugmakers need new ways to fill clinical trials
While about 89% of clinical trials meet their enrollment goals, 48% of trial sites miss enrollment and timeline goals, according to the Tufts Center for the Study of Drug Development. About 90% of drugmakers and research organizations use conventional methods such as physician referrals and mass media advertising to enroll participants, and only about 14% use social media, online data mining and electronic health records to recruit participants. "The emergence of open innovation models, where scientists worldwide openly share knowledge, and novel partnerships and alliances hold significant promise to transform the nature, pace, and cost of new drug development," said Kenneth Kaitin, the center's research director. Pharmalot.com/Pharma blog (1/15), PharmaTimes (U.K.) (1/17)       | Health Care & Policy | | | | - Drugmakers focus on rare diseases, genetic targets
More than 5,400 drug candidates are being tested in patients, including many for rare diseases and disorders for which no new drugs have been introduced in 10 or more years, according to a report sponsored by Pharmaceutical Research and Manufacturers of America. Hundreds of drugs being studied target genetic variations or are based on genes or cloned antibodies. Yahoo/The Associated Press (1/16) - Researchers inch toward a vaccine for Alzheimer's disease
Researchers at Université Laval and GlaxoSmithKline are reporting success in using monophosphoryl lipid A to stimulate the nervous system's immune response to Alzheimer's disease in mice. Weekly injections of MPL over 12 weeks eliminated up to 80% of brain plaques and improved the mice's cognitive function, researchers say. GSK has used the molecule as a vaccine adjuvant for years. Salon (1/16) | Company & Financial News | | | | - Galapagos buys U.K. biotech for $1.6M in cash
Cangenix, a gene-to-structure biotech firm that offers drug discovery services, has been acquired by Galapagos for $1.6 million upfront plus more than $700,000 in potential milestone fees. Galapagos said Cangenix's technology would complement its structure-based drug discovery unit, Argenta. "The assets and expertise of Cangenix really address a growing client need at Argenta. We look forward to extending and expanding this business," Galapagos CEO Onno van de Stolpe said. Pharmaceutical Business Review Online (1/16), PharmaTimes (U.K.) (1/16) - $200M Singapore plant will be Amgen's first in Asia
Amgen plans to invest about $200 million to construct a manufacturing plant at the Tuas Biomedical Park in Singapore. Work on the facility, Amgen's first in Asia, is expected to start within months. The plant's first products will be antibody drugs. Reuters (1/16) - Rothamsted plans more biotech trials
Maurice Moloney, director of Rothamsted Research, announced that the institute will conduct more biotech trials over the next five years. Aside from an aphid-resistant wheat, the institute is also developing an omega-3 variety of rapeseed that could replace wild fish in food for farmed salmon. Farmers Guardian (U.K.) (1/11)  | Earn American Airlines AAdvantage® miles from your business expenses and enjoy exclusive rewards and benefits
• Earn 30,000 American Airlines AAdvantage® bonus miles*
• First eligible checked bag is free*
• Priority Boarding*
• Double AAdvantage® miles on eligible business purchases*
*Learn more. |
  | Industrial & Environmental | | | | - Canadian cellulosic ethanol project gets $37.5M in new funding
Waste Management and EB Investments made additional investments amounting to $37.5 million in a waste-to-ethanol plant that Enerkem is building in Alberta, Canada. The plant is expected to initially make methanol for Methanex before ethanol production commences in 2014. Waste Management and EB Investments each poured in about $7.5 million into the project in 2011. Bloomberg Businessweek (1/17) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | If I had my life to live over, I would perhaps have more actual troubles but I'd have fewer imaginary ones."
--Don Herold,
American humorist, writer and cartoonist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, January 17, 2013
- Wednesday, January 16, 2013
- Tuesday, January 15, 2013
- Monday, January 14, 2013
- Friday, January 11, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment